Figure 5.

ARNAX + tumor‐associated antigen (TAA) enhances the therapeutic efficacy of programmed death ligand‐1 (PD‐L1) blockade and prolongs survival times. A, B, PD‐L1^lo EG7‐ or PD‐L1^hi EG7‐bearing mice were s.c. given PBS or 10 μg ARNAX‐120 + ovalbumin (OVA) 7 d after tumor implantation. Isotype control Ab or anti‐PD‐L1 Ab was ip given on days 7, 10, 13 and 16. PD‐L1, programmed death ligand‐1. C, MO5‐bearing mice were s.c. given PBS or 50 μg ARNAX‐140 + OVA 10 d after tumor implantation. Isotype control Ab or anti‐PD‐L1 Ab was ip given on days 10, 12, 14, 16, 18 and 20. (Left of A‐C) Tumor sizes were evaluated in each group. Error bars indicate means ± SEM; n = 5‐6 per group. Kruskal‐Wallis test with Dunn's multiple comparison test (A) and 1‐way analysis of variance (ANOVA) with Bonferroni's test (B,C) were carried out to analyze statistical significance; *P < .05, **P < .01 ***P < .001. (Right of A‐C) Mice were killed when tumor volumes reached 2500 mm³, and survival data were analyzed. Log‐rank test with Bonferroni's test were carried out to analyze statistical significance; *P < .05, **P < .01